Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

Purpose In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced solid tumors as monotherapy and in combination with pembrolizumab, an an...

Full description

Bibliographic Details
Main Authors: Ying Zhu, Tao Huang, John Powderly, Aung Naing, Manish R Patel, Matthew H Taylor, Rong Deng, Kyu Hong, Luke Chung, Hongyu Tian, Wen Hong Lin, Paul Woodard, Nathan Siemers, Hong Xiang, Donna Valencia, X Charlene Liao, Xiao Min Schebye
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/11/e010006.full

Internet

https://jitc.bmj.com/content/12/11/e010006.full

Similar Items